Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform
Toxicological Sciences · 2023
DOI: 10.1093/toxsci/kfac108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2023. Verfasst von Roberta Visone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, 20133, Italy. Hauptthemen laut MEDLINE: Drug Evaluation, Preclinical, Induced Pluripotent Stem Cells, Long QT Syndrome, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon 2020, Marie Skłodowska-Curie.
Abstract (Originalsprache)
Determining the potential cardiotoxicity and pro-arrhythmic effects of drug candidates remains one of the most relevant issues in the drug development pipeline (DDP). New methods enabling to perform more representative preclinical in vitro studies by exploiting induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) are under investigation to increase the translational power of the outcomes. Here we present a pharmacological campaign conducted to evaluate the drug-induced QT alterations and arrhythmic events on uHeart, a 3D miniaturized in vitro model of human myocardium encompassing iPSC-CM and dermal fibroblasts embedded in fibrin. uHeart was mechanically trained resulting in synchronously beating cardiac microtissues in 1 week, characterized by a clear field potential (FP) signal that was recorded by means of an integrated electrical system. A drug screening protocol compliant with the new International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines was established and uHeart was employed for testing the effect of 11 compounds acting on single or multiple cardiac ion channels and well-known to elicit QT prolongation or arrhythmic events in clinics. The alterations of uHeart’s electrophysiological parameters such as the beating period, the FP duration, the FP amplitude, and the detection of arrhythmic events prior and after drug administration at incremental doses were effectively analyzed through a custom-developed algorithm. Results demonstrated the ability of uHeart to successfully anticipate clinical outcome and to predict the QT prolongation with a sensitivity of 83.3%, a specificity of 100% and an accuracy of 91.6%. Cardiotoxic concentrations of drugs were notably detected in the range of the clinical highest blood drug concentration (Cmax), qualifying uHeart as a fit-to-purpose preclinical tool for cardiotoxicity studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, 20133, Italy.
- BiomimX Srl, Milan, 20158, Italy.
- Accelera Srl, Milan, 20014, Italy.
- Department of Computer Science, Università degli Studi di Milano, Milan, 20133, Italy.
ORCID-Profile: Paola Occhetta
Förderung
- European Union’s Horizon 2020
- Marie Skłodowska-Curie
Zitieren
APA
Visone, R., Lozano-Juan, F., Marzorati, S., Rivolta, M. W., Pesenti, E., Redaelli, A., Sassi, R., Rasponi, M., & Occhetta, P. (2023). Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfac108
Vancouver
Visone R, Lozano-Juan F, Marzorati S, Rivolta MW, Pesenti E, Redaelli A, et al. Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform. Toxicological Sciences. 2023. doi:10.1093/toxsci/kfac108
BibTeX
@article{Visone2023,
author = {Visone, Roberta and Lozano-Juan, Ferran and Marzorati, Simona and Rivolta, Massimo Walter and Pesenti, Enrico and Redaelli, Alberto and Sassi, Roberto and Rasponi, Marco and Occhetta, Paola},
title = {Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform},
journal = {Toxicological Sciences},
year = {2023},
doi = {10.1093/toxsci/kfac108}
}
EUVIMED